WallStSmart

AstraZeneca PLC (AZN)vsGlucoTrack Inc (GCTK)

VS
⚡

Smart Verdict

WallStSmart Research — data-driven comparison

AZN leads profitability with a 17.7% profit margin vs 0.0%. AZN earns a higher WallStSmart Score of 68/100 (B-).

AZN

Strong Buy

68

out of 100

Grade: B-

Growth: 6.7Profit: 8.5Value: 6.0Quality: 5.5
Piotroski: 6/9Altman Z: 1.48

GCTK

Avoid

26

out of 100

Grade: F

Growth: 4.3Profit: 3.0Value: 5.0Quality: 4.5
Piotroski: 2/9Altman Z: -34.50
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

AZNUndervalued (+4.3%)

Margin of Safety

+4.3%

Fair Value

$197.94

Current Price

$185.48

$12.46 discount

UndervaluedFair: $197.94Overvalued

Intrinsic value data unavailable for GCTK.

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

AZN5 strengths · Avg: 8.6/10
Market CapQuality
$293.73B10/10

Mega-cap, among the largest globally

Return on EquityProfitability
21.3%9/10

Every $100 of equity generates 21 in profit

Operating MarginProfitability
29.6%8/10

Strong operational efficiency at 29.6%

EPS GrowthGrowth
23.5%8/10

Earnings expanding 23.5% YoY

Free Cash FlowQuality
$3.99B8/10

Generating 4.0B in free cash flow

GCTK1 strengths · Avg: 10.0/10
Debt/EquityHealth
-0.0110/10

Conservative balance sheet, low leverage

Areas to Watch

AZN2 concerns · Avg: 3.0/10
P/E RatioValuation
26.8x4/10

Moderate valuation

Altman Z-ScoreHealth
1.482/10

Distress zone — elevated risk

GCTK4 concerns · Avg: 3.5/10
Revenue GrowthGrowth
0.0%4/10

0.0% revenue growth

EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Market CapQuality
$650,5103/10

Smaller company, higher risk/reward

Profit MarginProfitability
0.0%3/10

0.0% margin — thin

Comparative Analysis Report

WallStSmart Research

Bull Case : AZN

The strongest argument for AZN centers on Market Cap, Return on Equity, Operating Margin. Profitability is solid with margins at 17.7% and operating margin at 29.6%. PEG of 1.35 suggests the stock is reasonably priced for its growth.

Bull Case : GCTK

The strongest argument for GCTK centers on Debt/Equity.

Bear Case : AZN

The primary concerns for AZN are P/E Ratio, Altman Z-Score.

Bear Case : GCTK

The primary concerns for GCTK are Revenue Growth, EPS Growth, Market Cap.

Key Dynamics to Monitor

AZN profiles as a mature stock while GCTK is a value play — different risk/reward profiles.

GCTK carries more volatility with a beta of 0.73 — expect wider price swings.

AZN is growing revenue faster at 6.7% — sustainability is the question.

AZN generates stronger free cash flow (4.0B), providing more financial flexibility.

Bottom Line

AZN scores higher overall (68/100 vs 26/100), backed by strong 17.7% margins. Both earn "Strong Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

AstraZeneca PLC

HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA

AstraZeneca PLC discovers, develops, manufactures and markets prescription drugs in the areas of oncology, cardiovascular, renal and metabolism, respiratory, infections, neuroscience and gastroenterology worldwide. The company is headquartered in Cambridge, the United Kingdom.

GlucoTrack Inc

HEALTHCARE · MEDICAL DEVICES · USA

GlucoTrack, Inc., a medical device company, designs, develops and markets noninvasive glucose monitoring devices for people with diabetes and prediabetes in Europe and Asia Pacific. The company is headquartered in Or Yehuda, Israel.

Visit Website →

Want to dig deeper into these stocks?